Mr Shukla – Woodland Hospital Kettering


Rothwell Road


NN16 8XF

Opening hours

Monday: 5pm – 7pm

Tuesday; 8am – 6pm

Wednesday: 1pm – 7pm

Thursday: 1pm – 7pm

Friday: 5pm – 7pm

Saturday: 8am – 2pm




Book a consultation

Contact us to book your consultation.


Mr Divyang Shukla – consultant orthopaedic surgeon  specialises in knee and shoulder surgery and early intervention clinic and reconstruction clinic at Woodland Hospital, Kettering 

  • 1. E Kon, L.E., P Verdonk, S Nehrer, G Filardo, Autologous Protein Solution Injections for the Treatment of Knee Osteoarthritis 3-Year Results. The American Journal of Sports Medicine, 2020. 48(11): p. 2703-2710
  • 2. Matuska A, O’Shaughnessey K, King, W., Woodell-May J. (2013): Autologous solution protects bovine cartilage explants from IL-1. and TNF.-induced cartilage degradation. Journal of Orthopaedic Research. 31(12):1929-35.
  • 3. Prospective Post-Market Data Collection on Patients with Knee Osteoarthritis and Treated with nSTRIDE Autologous Protein Solution, in REGP-22-00 PROGRESS III. 2020: Clinical Investigation Report.
  • 4. J Hix, M.K., R Foreman, E Cullen, K Toler, W King, J Woodell-May, An Autologous Anti-Inflammatory Protein Solution Yielded a Favorable Safety Profile and Significant Pain Relief in an Open-Label Pilot Study of Patients with Osteoarthritis. BioResearch Open Access, 2017. 6(1): p. 151-158.
  • 5. van der Weegen W, van Drumpt R, Toler KO, Macenski MM. (2015): Safety and outcomes following a single Autologous Protein Solution injection for knee osteoarthritis: A Pilot Study. International Cartilage Repair Society, #6471, 8-11 May, Chicago, IL.
  • 6. O’Shaughnessey K., Matuska A., Hoeppner J., Farr J., Klaassen M., Kaeding C., Lattermann C., King W., Woodell-May J., “An Autologous Protein Solution prepared from the blood of osteoarthritic patients contains an enhanced profile of anti-inflammatory cytokines and anabolic growth factors,” Journal of Orthopaedic Research, 2014, 32(10):1349-55.
  • 7. APS IFU (01-50-1489)
  • 8. P Wehling, C.M., D Frisbie, et al, Autologous conditioned serum in the treatment of orthopedic diseases: the orthokine therapy. BioDrugs, 2007. 21(5): p. 323-32.
  • 9. A Multicenter, Double-Blind, Randomized, Placebo [Saline]-Controlled Pilot Study of a Single, Intra-Articular Injection of Autologous Protein Solution in Patients with Osteoarthritis of the Knee. Clinical Investigation Report – 36 Month, APSS-33-00, Version 1.0. 14. January 2019.† † As measured by WOMAC pain scores reported by patients continuing follow-up through 3 years (n = 19). 19 out of the original cohort of 31.
  • 10. Bertone AL, Ishihara A, Zekas LJ, et al. (2014): Evaluation of a single intra-articular injection of Autologous Protein Solution for treatment of osteoarthritis in horses. American Journal of Veterinary Medicine. 75(2):141-151.
  • 11. APSS-33-00 Clinical Investigation Report; Zimmer Biomet: “A Multicenter, Double-Blind, Randomized, Placebo [Saline]-Controlled Pilot Study of a Single, Intra-Articular Injection of Autologous Protein Solution in Patients with Osteoarthritis of the Knee-60 month;,” Ver. 1; July 1, 2021.
  • 13. NHS UK. (12 January 2021). Knee pain. NHS UK. https://www.nhs.uk/conditions/knee-pain/
  • 14. https://www.keele.ac.uk/media/keeleuniversity/ri/primarycare/bulletins/MusculoskeletalMatters1.pdf
  • 15. Nordqvist C. (2014): What Is Arthritis? What Causes Arthritis? Medical News Today. MediLexicon International. n.d. Web. 7 Aug. 2014. http://www.medicalnewstoday.com/articles/7621.php
  • 16. Osteoarthritis in General Practice: Data and Perspectives. Arthritis Research UK. 19 July 2013. n.d. Web. 8 Aug. 2015. http://www.arthritisresearchuk.org/ policy-and-public-affairs/reports- and-resources/reports.aspx
  • 17. NHS. (2021). Osteoarthritis. NHS UK. https://www.nhs.uk/conditions/osteoarthritis/
  • 18. Arthritis of the Knee-OrthoInfo – AAOS. American Academy of Orthopaedic Surgeons. n.d. Web. 8 Aug. 2014. http://orthoinfo.aaos.org/topic.cfm?topic=A0021
  • 19. Goldring MB. (2000): The role of the chondrocyte in osteoarthritis. Arthritis Rheum. 43(9):1916-1926.
  • 20. Woodell-May J, Matuska A, Oyster M, et al. (2011): Autologous protein solution inhibits MMP-13 production by IL-1beta and TNF alpha-stimulated human articular chondrocytes. Journal of Orthopaedic Research. 29 (9):1320-6
  • 22. Van Genechten et al. (2020): Autologous protein solution as selective treatment for advanced patellofemoral osteoarthritis in the middle-aged female patient: 54% response rate at 1year follow-up. Knee Surg Sports Traumatol Arthrosc 10-06064
  • 23. van Drumpt AM et al. (2016): Safety and Treatment Effectiveness of a Single Autologous Protein Solution Injection in Patients with Knee Osteoarthritis. BioResearch Open Access, Volume 5.1, p. 261 – 268
  • 24. Woodell-May J, Steckbeck K, King W. (2021): Potential Mechanism of Action of Current Point-of-Care Autologous Therapy Treatments for Osteoarthritis of the Knee—A Narrative Review. International Journal of Molecular Sciences (22) 2726
  • 25. King W, Bendele A, Marohl T, Woodell-May J (2017): Human blood-based anti-inflammtory solution inhibits osteoarthritis progression in a meniscal-tear rat study. Journal of Orthopaedic Research 2260-2268 DOI 10.1002/jor.23528
  • 26. Nicholas J. London, Larry E. Miller, Jon E. Block, Clinical & Economic Consequence of the treatment gap in knee osteoarthritis management, Medical Hypotheses, Volume 76, Issue 6, 2011, 887-892
  • 29. Wang K, Hyun K, Felson DT, Xu L, Kim DH, Nevitt MC, Yoshimura N., Kawaguchi H, Lin J, Kang X, Zhang Y. (2018): Radiographic Knee Osteoarthritis and Knee Pain: Cross-sectional study from Five Different Racial/ Ethnic Populations. Nature Scientific Reports 8:1364
  • 30. Kinds MB, Welsing PMJ, Vignon EP, Bijlsma JWJ, Viergever MA. (2011): A systematic review of the association between radiographic and clinical osteoarthritis of hip and knee. Osteoarthritis and Cartilage 19: 768-778.


  • ^Laboratory studies are not necessarily indicative of clinical outcomes.
  • *As measured by WOMAC pain scores reported by patients continuing follow-up through 3 years (n = 19).
  • 19 out of the original cohort of 31.

*nSTRIDE impacts on biochemical imbalance causing osteoarthritis as based on in-vitro and animal studies. Results are not necessarily typical, indicative, or representative of all recipient patients. Results will vary due to health, weight, activity and other variables. Not all patients are candidates for this product and/or procedure. Only a medical professional can determine the treatment appropriate for your specific condition. Not for distribution in France.